Chief Medical Officer · Centessa Pharmaceuticals plc (CNTA)

Stephen Kanes

FY2025 is the first fiscal year CompBrief holds for Stephen Kanes as a named executive officer of Centessa Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$6,812,680

Salary $519,034Stock awards $0Bonus $283,500

2nd of 3 named executive officers at Centessa Pharmaceuticals by FY2025 total.

3 named officers on file for Centessa Pharmaceuticals, FY2025

Stephen Kanes’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Centessa Pharmaceuticals’s whole pay program stands against its peers

  • Centessa Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CNTA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2026 (DEF 14A).

Free

Get Stephen Kanes’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Stephen Kanes compensation by year

Centessa Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Centessa Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$519,034
Bonus$283,500
Stock awards$0
Option awards$5,996,146
Non-equity incentive$0
Pension and deferred compensation$0
All other$14,000
Total$6,812,680

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Centessa Pharmaceuticals plc DEF 14A filed April 29, 2026, accession 0001847903-26-000040, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Centessa Pharmaceuticals plc filed document, accession 0001847903-26-000040. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option500,000—$16.90

Per the Outstanding Equity Awards at Fiscal Year-End table in Centessa Pharmaceuticals plc's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Centessa Pharmaceuticals’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Saurabh SahaFormer Chief Executive Officer$11,877,244
Stephen Kanes · this pageChief Medical Officer$6,812,680
John CrowleyChief Financial Officer$3,842,835

The full Centessa Pharmaceuticals compensation record

free company brief

This page is one person within Centessa Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Centessa Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Stephen Kanes's compensation dossier · One-time report. No refunds.